Table of Contents
To view the fulltext, log-in or choose pay-per-view options:
Get Access

Validation of Biochemical Markers for the Prediction of Liver Fibrosis and Necroinflammatory Activity in Hemodialysis Patients with Chronic Hepatitis C

Canbakan M.a · Senturk H.b · Canbakan B.b · Toptas T.f · Tabak O.g · Ozaras R.d · Tabak F.d · Balcı H.c · Sut N.h · Ozbay G.e
aDepartment of Nephrology, Haydarpasa Numune Training and Research Hospital, bDepartment of Gastroenterology, cFikret Biyal Central Research Laboratory, dDepartment of Infectious Diseases and Clinical Microbiology, and eDepartment of Pathology, Cerrahpasa Medical Faculty of Istanbul University, fDivision of Hematology, Marmara University Hospital, gDepartment of Internal Medicine, Istanbul Training and Research Hospital, Istanbul, and hDepartment of Biostatistics and Medical Informatics, Trakya University Medical Faculty, Edirne, Turkey Nephron Clin Pract 2011;117:c289–c295 (DOI:10.1159/000320751)


Background: Liver biopsy is an imperfect gold standard for assessing the disease severity in hemodialysis patients with chronic hepatitis C. Our purpose was to compare the accuracy of the FibroTest (FT) and ActiTest (AT) with liver biopsy and the AST-to-platelet ratio index (APRI) in determining hepatic fibrosis and necroinflammatory activity in hemodialysis patients with hepatitis C virus (HCV). Methods: The FT-AT index combining 6 biochemical markers was assessed in 33 hemodialysis patients with HCV. Liver fibrosis and necroinflammatory activity was staged and graded according to the METAVIR scoring system. Results: The accuracy of FT-AT versus biopsy was 0.46 for significant fibrosis and 0.36 for severe necroinflammatory activity. The FT index had a positive predictive value of 20% for scores greater than 0.6 and a negative predictive value of 45% for scores less than 0.2. Eleven of the 33 patients had scores ≤0.2, 6 had significant fibrosis on biopsy. Four out of 5 patients with FT scores >0.6 had mild fibrosis. APRI correlated well with the biopsy. Conclusion: The FT-AT test does not seem to be a reliable noninvasive marker for the prediction of necroinflammatory activity and fibrosis in hemodialysis patients with HCV and cannot be used as an alternative to either liver biopsy or APRI.


Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50